IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v547y2017i7662d10.1038_nature22991.html
   My bibliography  Save this article

An immunogenic personal neoantigen vaccine for patients with melanoma

Author

Listed:
  • Patrick A. Ott

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital
    Harvard Medical School)

  • Zhuting Hu

    (Dana-Farber Cancer Institute)

  • Derin B. Keskin

    (Dana-Farber Cancer Institute
    Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Sachet A. Shukla

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard)

  • Jing Sun

    (Dana-Farber Cancer Institute)

  • David J. Bozym

    (Dana-Farber Cancer Institute)

  • Wandi Zhang

    (Dana-Farber Cancer Institute)

  • Adrienne Luoma

    (Dana-Farber Cancer Institute)

  • Anita Giobbie-Hurder

    (Dana-Farber Cancer Institute)

  • Lauren Peter

    (Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
    Ragon Institute of MGH, MIT, and Harvard)

  • Christina Chen

    (Dana-Farber Cancer Institute)

  • Oriol Olive

    (Dana-Farber Cancer Institute)

  • Todd A. Carter

    (Broad Institute of MIT and Harvard)

  • Shuqiang Li

    (Broad Institute of MIT and Harvard)

  • David J. Lieb

    (Broad Institute of MIT and Harvard)

  • Thomas Eisenhaure

    (Broad Institute of MIT and Harvard)

  • Evisa Gjini

    (Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute)

  • Jonathan Stevens

    (Brigham and Women’s Hospital)

  • William J. Lane

    (Brigham and Women’s Hospital)

  • Indu Javeri

    (CuriRx, Inc.)

  • Kaliappanadar Nellaiappan

    (CuriRx, Inc.)

  • Andres M. Salazar

    (Oncovir, Inc.)

  • Heather Daley

    (Dana-Farber Cancer Institute)

  • Michael Seaman

    (Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center)

  • Elizabeth I. Buchbinder

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital
    Harvard Medical School)

  • Charles H. Yoon

    (Harvard Medical School
    Brigham and Women’s Hospital)

  • Maegan Harden

    (Broad Institute of MIT and Harvard)

  • Niall Lennon

    (Broad Institute of MIT and Harvard)

  • Stacey Gabriel

    (Broad Institute of MIT and Harvard)

  • Scott J. Rodig

    (Center for Immuno-Oncology (CIO), Dana-Farber Cancer Institute
    Brigham and Women’s Hospital)

  • Dan H. Barouch

    (Harvard Medical School
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
    Ragon Institute of MGH, MIT, and Harvard)

  • Jon C. Aster

    (Harvard Medical School
    Brigham and Women’s Hospital)

  • Gad Getz

    (Harvard Medical School
    Broad Institute of MIT and Harvard
    Massachusetts General Hospital)

  • Kai Wucherpfennig

    (Harvard Medical School
    Dana-Farber Cancer Institute)

  • Donna Neuberg

    (Dana-Farber Cancer Institute)

  • Jerome Ritz

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital
    Harvard Medical School)

  • Eric S. Lander

    (Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Edward F. Fritsch

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard
    Neon Therapeutics, Inc.)

  • Nir Hacohen

    (Harvard Medical School
    Broad Institute of MIT and Harvard
    Center for Cancer Research, Massachusetts General Hospital)

  • Catherine J. Wu

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital
    Harvard Medical School
    Broad Institute of MIT and Harvard)

Abstract

The results of a phase I trial assessing a personal neoantigen multi-peptide vaccine in patients with melanoma, showing feasibility, safety, and immunogenicity.

Suggested Citation

  • Patrick A. Ott & Zhuting Hu & Derin B. Keskin & Sachet A. Shukla & Jing Sun & David J. Bozym & Wandi Zhang & Adrienne Luoma & Anita Giobbie-Hurder & Lauren Peter & Christina Chen & Oriol Olive & Todd , 2017. "An immunogenic personal neoantigen vaccine for patients with melanoma," Nature, Nature, vol. 547(7662), pages 217-221, July.
    • Handle: RePEc:nat:nature:v:547:y:2017:i:7662:d:10.1038_nature22991
    DOI: 10.1038/nature22991
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature22991
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature22991?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Meghana Pagadala & Timothy J. Sears & Victoria H. Wu & Eva Pérez-Guijarro & Hyo Kim & Andrea Castro & James V. Talwar & Cristian Gonzalez-Colin & Steven Cao & Benjamin J. Schmiedel & Shervin Goudarzi , 2023. "Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    2. Luis F. Schachner & Christopher Mullen & Wilson Phung & Joshua D. Hinkle & Michelle Irwin Beardsley & Tracy Bentley & Peter Day & Christina Tsai & Siddharth Sukumaran & Tomasz Baginski & Danielle DiCa, 2024. "Exposing the molecular heterogeneity of glycosylated biotherapeutics," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    3. Jens Bauer & Natalie Köhler & Yacine Maringer & Philip Bucher & Tatjana Bilich & Melissa Zwick & Severin Dicks & Annika Nelde & Marissa Dubbelaar & Jonas Scheid & Marcel Wacker & Jonas S. Heitmann & S, 2022. "The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    4. Hakimeh Ebrahimi-Nik & Marmar Moussa & Ryan P. Englander & Summit Singhaviranon & Justine Michaux & HuiSong Pak & Hiroko Miyadera & William L. Corwin & Grant L. J. Keller & Adam T. Hagymasi & Tatiana , 2021. "Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
    5. Naomi Hoenisch Gravel & Annika Nelde & Jens Bauer & Lena Mühlenbruch & Sarah M. Schroeder & Marian C. Neidert & Jonas Scheid & Steffen Lemke & Marissa L. Dubbelaar & Marcel Wacker & Anna Dengler & Rei, 2023. "TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    6. Georges Bedran & Daniel A. Polasky & Yi Hsiao & Fengchao Yu & Felipe Veiga Leprevost & Javier A. Alfaro & Marcin Cieslik & Alexey I. Nesvizhskii, 2023. "Unraveling the glycosylated immunopeptidome with HLA-Glyco," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    7. Ashish Goyal & Jens Bauer & Joschka Hey & Dimitris N. Papageorgiou & Ekaterina Stepanova & Michael Daskalakis & Jonas Scheid & Marissa Dubbelaar & Boris Klimovich & Dominic Schwarz & Melanie Märklin &, 2023. "DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    8. John P. Finnigan & Jenna H. Newman & Yury Patskovsky & Larysa Patskovska & Andrew S. Ishizuka & Geoffrey M. Lynn & Robert A. Seder & Michelle Krogsgaard & Nina Bhardwaj, 2024. "Structural basis for self-discrimination by neoantigen-specific TCRs," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    9. Laura Y. Zhou & Fei Zou & Wei Sun, 2023. "Prioritizing candidate peptides for cancer vaccines through predicting peptide presentation by HLA‐I proteins," Biometrics, The International Biometric Society, vol. 79(3), pages 2664-2676, September.
    10. Jacopo Chiaro & Gabriella Antignani & Sara Feola & Michaela Feodoroff & Beatriz Martins & Hanne Cojoc & Salvatore Russo & Manlio Fusciello & Firas Hamdan & Valentina Ferrari & Daniele Ciampi & Ilkka I, 2023. "Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors," Nature Communications, Nature, vol. 14(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:547:y:2017:i:7662:d:10.1038_nature22991. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.